The treatment of mitochondrial myopathies and encephalomyopathies.
This paper briefly summarizes the results of a long-term, open pharmacotherapy trial in 16 patients with well-characterized mitochondrial disease. Outcome measures included repeated clinical evaluation, 31P-NMR spectroscopy and near-infrared spectroscopy. Treated patients appeared to survive longer with less functional disability and medical complications than typically seen in clinical practice.
Peterson
P L
PL
Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002648:Child; D003067:Coenzymes; D005260:Female; D006801:Humans; D007625:Kearns-Sayre Syndrome / Q000188:drug therapy* / Q000378:metabolism; D017241:MELAS Syndrome / Q000188:drug therapy* / Q000378:metabolism; D017243:MERRF Syndrome / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D017240:Mitochondrial Myopathies / Q000188:drug therapy* / Q000378:metabolism; D010085:Oxidative Phosphorylation; D010101:Oxygen Consumption; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use*
D000975:Antioxidants; D003067:Coenzymes; D014815:Vitamins; D014812:Vitamin K; D014451:Ubiquinone; D014810:Vitamin E; C024989:coenzyme Q10; D001205:Ascorbic Acid; D008775:Methylprednisolone